Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mehmet Kemal Samur, Ph.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Tai YT, Anderson KC, Qiu L, Munshi NC. YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 Jul 23; 136(4):468-479. PMID: 32187357.
    Citations:    
  2. Samur MK, Aktas Samur A, Fulciniti M, Szalat R, Han T, Shammas M, Richardson P, Magrangeas F, Minvielle S, Corre J, Moreau P, Thakurta A, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 Jul 20; JCO2000461. PMID: 32687451.
    Citations:    
  3. Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, Adamia S, Ando K, Hideshima T, Anderson KC. JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020 Jul 07. PMID: 32844992.
    Citations:    
  4. Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 Jun 24. PMID: 32589921.
    Citations:    
  5. Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger SN, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar MV. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight. 2020 Jun 18; 5(12). PMID: 32427579.
    Citations:    
  6. Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 Feb 24; 11(1):1095. PMID: 32094369.
    Citations:    
  7. Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Danziger SA, Ratushny A, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 Jul; 34(7):1866-1874. PMID: 32060406.
    Citations:    
  8. Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338. PMID: 31953400.
    Citations:    
  9. Alagpulinsa DA, Kumar S, Talluri S, Nanjappa P, Buon L, Chakraborty C, Samur MK, Szalat R, Shammas MA, Munshi NC. Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Adv. 2019 12 10; 3(23):3968-3972. PMID: 31805191.
    Citations:    
  10. Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yasumizu Y, Hong D, Samur M, Kufe D. Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. Oncogene. 2019 Nov; 38(47):7278. PMID: 31576011.
    Citations:    
  11. Hata T, Rajabi H, Takahashi H, Yasumizu Y, Li W, Jin C, Long MD, Hu Q, Liu S, Fushimi A, Yamashita N, Kui L, Hong D, Yamamoto M, Miyo M, Hiraki M, Maeda T, Suzuki Y, Samur MK, Kufe D. MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. Cancer Res. 2019 11 15; 79(22):5711-5722. PMID: 31519689.
    Citations:    
  12. Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, Mitchell TJ, Fullam A, Gonzalez S, Szalat R, Abascal F, Rodriguez-Martin B, Samur MK, Glodzik D, Roncador M, Fulciniti M, Tai YT, Minvielle S, Magrangeas F, Moreau P, Corradini P, Anderson KC, Tubio JMC, Wedge DC, Gerstung M, Avet-Loiseau H, Munshi N, Campbell PJ. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835. PMID: 31444325.
    Citations:    
  13. Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yasumizu Y, Hong D, Samur M, Kufe D. MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. Oncogene. 2019 11; 38(47):7266-7277. PMID: 31435022.
    Citations:    
  14. Hata T, Rajabi H, Yamamoto M, Jin C, Ahmad R, Zhang Y, Kui L, Li W, Yasumizu Y, Hong D, Miyo M, Hiraki M, Maeda T, Suzuki Y, Takahashi H, Samur M, Kufe D. Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 10; 18(10):1744-1754. PMID: 31308076.
    Citations:    
  15. Ho M, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC, O'Gorman P, Bianchi G. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia. 2020 01; 34(1):196-209. PMID: 31142847.
    Citations:    
  16. Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39. PMID: 30914633.
    Citations:    
  17. Bae J, Samur M, Richardson P, Munshi NC, Anderson KC. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226. PMID: 30872779.
    Citations:    
  18. Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6. PMID: 30590042.
    Citations:    Fields:    
  19. Cleynen A, Samur M, Perrot A, Buisson L, Maheo S, Fulciniti M, Attal M, Munshi N, Avet-Loiseau H, Corre J. Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood. 2018 12 27; 132(26):2778-2780. PMID: 30429160.
    Citations:    Fields:    
  20. Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946. PMID: 30401751.
    Citations:    
  21. Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, Johnson D, Bertsch U, Broyl A, van Duin M, Shah R, Johansen P, Nørgaard MA, Samworth RJ, Sonneveld P, Goldschmidt H, Morgan GJ, Orfao A, Munshi N, Johnson HE, El-Galaly T, Dybkær K, Bøgsted M. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood Adv. 2018 09 25; 2(18):2400-2411. PMID: 30254104.
    Citations:    
  22. Kumar S, Talluri S, Pal J, Yuan X, Lu R, Nanjappa P, Samur MK, Munshi NC, Shammas MA. Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance. Blood Cancer J. 2018 09 25; 8(10):92. PMID: 30301882.
    Citations:    Fields:    
  23. Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, Martincorena I, Dawson KJ, Samur MK, Zamora J, Tarpey P, Davies H, Fulciniti M, Shammas MA, Tai YT, Magrangeas F, Moreau P, Corradini P, Anderson K, Alexandrov L, Wedge DC, Avet-Loiseau H, Campbell P, Munshi N. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018 08 22; 9(1):3363. PMID: 30135448.
    Citations: 1     Fields:    Translation:Humans
  24. Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018 09 06; 132(10):1050-1063. PMID: 29997223.
    Citations:    Fields:    
  25. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170. PMID: 29967379.
    Citations: 1     Fields:    
  26. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597. PMID: 29884741.
    Citations: 2     Fields:    
  27. Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, Munshi NC, Mayr C, Leslie CS. Widespread intronic polyadenylation diversifies immune cell transcriptomes. Nat Commun. 2018 04 30; 9(1):1716. PMID: 29712909.
    Citations:    Fields:    Translation:HumansCells
  28. Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635. PMID: 29749396.
    Citations: 1     Fields:    
  29. Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, Alexandrov LB, Fullam A, Martincorena I, Dawson KJ, Angelopoulos N, Samur MK, Szalat R, Zamora J, Tarpey P, Davies H, Corradini P, Anderson KC, Minvielle S, Neri A, Avet-Loiseau H, Keats J, Campbell PJ, Munshi NC, Bolli N. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018 04; 32(4):1044-1048. PMID: 29209044.
    Citations:    Fields:    
  30. Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018 04; 32(4):996-1002. PMID: 29158558.
    Citations: 1     Fields:    
  31. Gu Y, Xu K, Torre C, Samur M, Barwick BG, Rupji M, Arora J, Neri P, Kaufman J, Nooka A, Bernal-Mizrachi L, Vertino P, Sun SY, Chen J, Munshi N, Fu H, Kowalski J, Boise LH, Lonial S. 14-3-3? binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia. 2018 03; 32(3):744-751. PMID: 28924240.
    Citations:    Fields:    
  32. Rajabi H, Hiraki M, Tagde A, Alam M, Bouillez A, Christensen CL, Samur M, Wong KK, Kufe D. MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep. 2017 08 07; 7(1):7481. PMID: 28785086.
    Citations: 4     Fields:    
  33. Munshi N, Samur MK, Gregory W. Myeloma Minimal Residual Disease and Surrogacy-Reply. JAMA Oncol. 2017 08 01; 3(8):1136-1137. PMID: 28494053.
    Citations:    Fields:    
  34. Gülkesen KH, Isleyen F, Cinemre B, Samur MK, Sen Kaya S, Zayim N. A Web-based Game for Teaching Facial Expressions to Schizophrenic Patients. Appl Clin Inform. 2017 Jul 12; 8(3):719-730. PMID: 28696479.
    Citations:    Fields:    Translation:Humans
  35. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6. PMID: 28669490.
    Citations: 5     Fields:    Translation:HumansCells
  36. Szalat R, Samur MK, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, Wen K, Kumar S, Perini T, Calkins AS, Reznichenko E, Chauhan D, Tai YT, Shammas MA, Anderson KC, Fermand JP, Arnulf B, Avet-Loiseau H, Lazaro JB, Munshi NC. Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2018 01; 32(1):111-119. PMID: 28588253.
    Citations: 1     Fields:    Translation:HumansCells
  37. Song Y, Li S, Ray A, Das DS, Qi J, Samur MK, Tai YT, Munshi N, Carrasco RD, Chauhan D, Anderson KC. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017 10 05; 36(40):5631-5638. PMID: 28581522.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  38. Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237. PMID: 28442502.
    Citations:    Fields:    Translation:HumansAnimalsCells
  39. Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017 07 13; 36(28):4037-4046. PMID: 28288138.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  40. Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289. PMID: 28270494.
    Citations: 3     Fields:    Translation:HumansCells
  41. Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245. PMID: 28096095.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  42. Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319. PMID: 28082445.
    Citations: 1     Fields:    Translation:HumansCells
  43. Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017 Jan 01; 3(1):28-35. PMID: 27632282.
    Citations: 14     Fields:    Translation:Humans
  44. Nandi B, Shapiro M, Samur MK, Pai C, Frank NY, Yoon C, Prabhala RH, Munshi NC, Gold JS. Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. Oncoimmunology. 2016 Aug; 5(8):e1189052. PMID: 27622061.
    Citations: 3     
  45. Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, Adamia S, Neri A, Hunter ZR, Treon SP, Anderson KC, Tassone P, Munshi NC. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15; 6:e380. PMID: 26771806.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  46. Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258. PMID: 26728187.
    Citations: 16     Fields:    Translation:HumansCells
  47. Shapiro M, Nandi B, Pai C, Samur MK, Pelluru D, Fulciniti M, Prabhala RH, Munshi NC, Gold JS. Deficiency of IL-17A, but not the prototypical Th17 transcription factor ROR?t, decreases murine spontaneous intestinal tumorigenesis. Cancer Immunol Immunother. 2016 Jan; 65(1):13-24. PMID: 26559812.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  48. Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18. PMID: 25979485.
    Citations: 49     Fields:    Translation:HumansCells
  49. Bae J, Samur M, Munshi A, Hideshima T, Keskin D, Kimmelman A, Lee AH, Dranoff G, Anderson KC, Munshi NC. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914. PMID: 25941601.
    Citations: 4     
  50. Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC. Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7. PMID: 25237203.
    Citations: 17     Fields:    Translation:Humans
  51. Samur MK. RTCGAToolbox: a new tool for exporting TCGA Firehose data. PLoS One. 2014; 9(9):e106397. PMID: 25181531.
    Citations: 21     Fields:    Translation:Humans
  52. Isleyen F, Gulkesen KH, Cinemre B, Samur MK, Zayim N, Sen Kaya S. Evaluation of the usability of a serious game aiming to teach facial expressions to schizophrenic patients. Stud Health Technol Inform. 2014; 205:662-6. PMID: 25160269.
    Citations: 1     Fields:    Translation:Humans
  53. Samur MK, Shah PK, Wang X, Minvielle S, Magrangeas F, Avet-Loiseau H, Munshi NC, Li C. The shaping and functional consequences of the dosage effect landscape in multiple myeloma. BMC Genomics. 2013 Oct 02; 14:672. PMID: 24088394.
    Citations: 6     Fields:    Translation:HumansCells
  54. Samur MK, Yan Z, Wang X, Cao Q, Munshi NC, Li C, Shah PK. canEvolve: a web portal for integrative oncogenomics. PLoS One. 2013; 8(2):e56228. PMID: 23418540.
    Citations: 12     Fields:    Translation:Humans
  55. Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71. PMID: 23293352.
    Citations: 15     Fields:    Translation:HumansCells
  56. Yan Z, Shah PK, Amin SB, Samur MK, Huang N, Wang X, Misra V, Ji H, Gabuzda D, Li C. Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res. 2012 Sep 01; 40(17):e135. PMID: 22645320.
    Citations: 33     Fields:    Translation:HumansCells
  57. Bozkurt S, Zayim N, Gulkesen KH, Samur MK, Karaagaoglu N, Saka O. Usability of a web-based personal nutrition management tool. Inform Health Soc Care. 2011 Dec; 36(4):190-205. PMID: 21345010.
    Citations: 2     Fields:    Translation:Humans
  58. Bozcuk HS, Artac M, Akcan S, Korgun DK, Ozben T, Ozdogan M, Samur M, Mutlu H, Kargi A, Savas B. Does serum VEGF predict prognosis in metastatic colorectal carcinoma patients treated with XELIRI? J Clin Oncol. 2006 Jun 20; 24(18_suppl):13548. PMID: 27952173.
    Citations:    
  59. Bozcuk HS, Gumus A, Ozbilim G, Sarper A, Ozdogan M, Artac M, Samur M, Savas B. Recursive partitioning analysis of selected molecular markers to predict mediastinal lymph node involvement in operable non-small cell lung cancer (NSCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7320. PMID: 27945075.
    Citations:    
  60. Savas B, Bozcuk H, Özdo M, Karaveli F, Pe E, Artaç M, Aykut A, Samur M. Molecular and clinical parameters which determine the docetaxel response in metastatic breast cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9732. PMID: 28014360.
    Citations:    
  61. Bozcuk HS, Dalmis B, Samur M, Savas B, Ozdogan M, Artac M, Yildiz M. Are baseline performance status and line of chemotherapy administration important for palliation of metastatic non-small cell lung cancer (NSCLC) with chemotherapy? J Clin Oncol. 2004 Jul 15; 22(14_suppl):8175. PMID: 28015398.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Samur's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (255)
Explore
_
Co-Authors (51)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.